850
Participants
Start Date
February 22, 2021
Primary Completion Date
September 6, 2022
Study Completion Date
September 9, 2022
RV3-BB
1.0 mL of the thawed rotavirus vaccine to be administered orally at birth, 6 weeks and 10 weeks of age
Trivalent P2-VP8
0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age
Rotarix
1.5 mL of the liquid vaccine containing the RIX4414 strain of human rotavirus vaccine to be administered orally at 6 weeks and 10 weeks of age.
RV3-BB birth dose
1.0 mL of the thawed rotavirus vaccine to be administered orally at birth.
Trivalent P2-VP8 Booster dose
0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at 14 weeks of age
Wits RHI Shandukani Research Centre, Johannesburg
Vaccine and Infectious Diseases Analytics (VIDA) - formerly known as Respiratory and Meningococcal Pathogens Research Unit (RMPRU), Johannesburg
Collaborators (1)
SK Bioscience Co., Ltd.
INDUSTRY
Murdoch Childrens Research Institute
OTHER
Children's Hospital Medical Center, Cincinnati
OTHER
Bill and Melinda Gates Foundation
OTHER
PATH
OTHER